Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul:6:1124-1133.
doi: 10.1200/GO.20.00012.

Comparison of Access to Novel Drugs for Lymphoma and Chronic Lymphocytic Leukemia Between India and the United States

Vishwanath Sathyanarayanan  1 , Christopher R Flowers  2 , Swaminathan P Iyer  2
Affiliations
Review

Comparison of Access to Novel Drugs for Lymphoma and Chronic Lymphocytic Leukemia Between India and the United States

Vishwanath Sathyanarayanan et al. JCO Glob Oncol. 2020 Jul.

Abstract

This review will compare and contrast the costs and access to novel drugs for treating chronic lymphocytic leukemia (CLL) and lymphoma in the United States and India during the last 5 years. Clinical outcomes for patients with hematologic malignancies have improved significantly since the approval of immunotherapeutic and targeted therapies. These new treatments have had an impact on overall outcomes and have helped determine the design for translational research and future trials. Although most of these novel drugs called "innovators" are initially approved and marketed in the United States, several have also become available in countries such as India. With the expiration of patents, generic versions of innovator drugs have increased and accessibility has improved for patients. The advent of biosimilars is another route for expanding access to biologic compounds. As a result, the development costs for developing these drugs are lower, and consequently, the costs for the patient are often lower. Although the delivery of cancer care is not the same in India as it is in the United States, the introduction of biosimilars and generics has helped bridge the gap. This has made treatment of CLL and lymphoma similar in both countries and has had the same impact on patient outcomes and quality of life. Compulsory licensing for essential medications, as stipulated by the Doha Declaration, and capping of drug prices could improve global access to treatments for CLL and lymphoma.

PubMed Disclaimer

Conflict of interest statement

Vishwanath Sathyanarayanan

Honoraria: Dr. Reddy’s Laboratories, Alkem Laboratories, Lupin

Christopher R. Flowers

Consulting or Advisory Role: Abbvie, Bayer, Celgene (unpaid), Denovo Biopharma, Genentech/Roche, Gilead, OptumRx, Karyopharm, Pharmacyclics/ Janssen, Spectrum

Research Funding: Abbvie, Acerta, Celgene, Gilead, Genentech/Roche, Janssen Pharmaceutical, Millennium/Takeda, Pharmacyclics, TG Therapeutics, Burroughs Wellcome Fund, V Foundation

Swaminathan P. Iyer

Honoraria: Seattle Genetics

Consulting or Advisory Role: Daiichi Sankyo, Seattle Genetics, Legend Biotech

Research Funding: Bristol-Myers Squibb (Inst), Takeda (Inst), Novartis (Inst), Genentech (Inst), Rhizen Pharmaceuticals (Inst), Seattle Genetics (Inst), CRISPR Therapeutics (Inst), Spectrum Pharmaceuticals (Inst),

Trillium Therapeutics (Inst), Affimed Therapeutics (Inst)

Travel, Accommodations, Expenses: Takeda, Gilead Sciences

No other potential conflicts of interest were reported.

Similar articles

See all similar articles

Cited by

References

    1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. - PubMed
    1. Saxena R, Kumar R, Sazawal S, et al. CLL in India may have a different biology from that in the West. Blood. 2016;128 abstract 5574.
    1. US Food and Drug Administration Hematology/Oncology (Cancer) Approvals & Safety Notifications. https://www.fda.gov/drugs/resources-information-approved-drugs/hematolog...
    1. Central Drugs Standard Control Organisation Homepagehttps://www.cdscoonline.gov.in/CDSCO/homepage
    1. Papanicolas I, Woskie LR, Jha AK. Health care spending in the United States and other high-income countries. JAMA. 2018;319:1024–1039. - PubMed

Substances